Jo Piper

SMIM1 absence is associated with reduced energy expenditure and excess weight

Luca Stefanucci, Camous Moslemi, Ana R. Tomé, Sam Virtue et autres

BACKGROUND: Obesity rates have nearly tripled in the past 50 years, and by 2030 more than 1 billion individuals worldwide are projected to be obese. This creates a significant economic strain due to the associated non-communicable diseases. The root cause is an …

gb, dk, ee (code pays fourni par la source)

Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial

Alasdair Peter Stuart Munro, Shuo Feng, Leila Janani, Victoria R. Cornelius et autres

BACKGROUND: Some high-income countries have deployed fourth doses of COVID-19 vaccines, but the clinical need, effectiveness, timing, and dose of a fourth dose remain uncertain. We aimed to investigate the safety, reactogenicity, and immunogenicity of fourth-dose boosters against COVID-19. METHODS: The COV-BOOST …

gb (code pays fourni par la source)

Loss of function variant in SMIM1 is associated with reduced energy expenditure and weight gain

Mattia Frontini, Luca Stefanucci, Camous Moslemi, Ana R. Tomé et autres

gb, dk, ee, au, us, se (code pays fourni par la source)

Challenges and opportunities for conducting a vaccine trial during the COVID-19 pandemic in the United Kingdom

M. Estée Török, Benjamin R. Underwood, Mark R. Toshner, Claire S. Waddington et autres

The COVID-19 pandemic has resulted in unprecedented challenges for healthcare systems worldwide. It has also stimulated research in a wide range of areas including rapid diagnostics, novel therapeutics, use of technology to track patients and vaccine development. Here, we describe our experience …

gb (code pays fourni par la source)

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Merryn Voysey, Sue Ann Costa Clemens, Shabir Ahmed Madhi, Lily Yin Weckx et autres

BACKGROUND: The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, with a regimen of two standard doses given with an interval of 4-12 weeks. The planned roll-out in the …

gb, it, Afrique du Sud, br (code pays fourni par la source)

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Merryn Voysey, Sue Ann Costa Clemens, Shabir Ahmed Madhi, Lily Yin Weckx et autres

Background A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled …

gb, it, Afrique du Sud, br, us, fr (code pays fourni par la source)

Somatic cancer genetics in the UK: real-world data from phase I of the Cancer Research UK Stratified Medicine Programme

Colin R. Lindsay, Emily Clare Shaw, Fiona Helen Blackhall, Kevin G. Blyth et autres

Introduction Phase I of the Cancer Research UK Stratified Medicine Programme (SMP1) was designed to roll out molecular pathology testing nationwide at the point of cancer diagnosis, as well as facilitate an infrastructure where surplus cancer tissue could be used for research. …

gb (code pays fourni par la source)

Study of fully submerged point absorber wave energy converter - modelling, simulation and scaled experiment

Boyin Ding, L. da Silva, Nataliia Y. Sergiienko, Fanmin Meng et autres

Boyin Ding, Leandro Souza Pinheiro da Silva, Nataliia Sergiienko, Fantai Meng, Jonathan David Piper, Luke Bennetts, Markus Wagner, Benjamin Cazzolato, Maziar Arjomandi

Long-term effect of introducing an early warning score on respiratory rate charting on general wards

Jackie McBride, Debbie Knight, Jo Piper, Gary B. Smith

gb (code pays fourni par la source)

Care Tracker

J. John Mann, Carol Seaver, Jo Piper, C Hokans et autres

The shift from inpatient to ambulatory settings and the increasingly large and diverse numbers of ambulatory clients require reengineering and cost-effective approaches to managing ambulatory care. With data on 921 encounters in 12 ambulatory clinics, we developed CARE TRACKER, an instrument to …

us (code pays fourni par la source)

[ENERGY EXPENDITURE IN RUNNING, IN DOGS].

P. Cerretelli, Jo Piper, Federica Mangili, Benjamin Ricci et autres